CC-1088

Boston Medical Center · Phase 2 active Small molecule

At a glance

Generic name	CC-1088
Sponsor	Boston Medical Center
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes (PHASE2)
Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CC-1088 CI brief — competitive landscape report
CC-1088 updates RSS · CI watch RSS
Boston Medical Center portfolio CI